Reason: Acquired by Biosynex
Last recorded trade on: June 30, 2023
Source: https://www.globenewswire.com/en/news-release/2023/04/27/2656944/21088/en/Biosynex-Completes-Acquisition-of-Chembio-Diagnostics-Inc.html
P/E ratio for Chembio Diagnostics (CEMI)
P/E ratio on June 30, 2023 (TTM): -0.3792
According to Chembio Diagnostics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.379167. At the end of 2021 the company had a P/E ratio of -0.8261.
P/E ratio history for Chembio Diagnostics from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -0.8261 | -76.7% |
| 2020 | -3.54 | |
| 2012 | 43.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 QuidelOrtho QDEL | -5.12 | 1,249.99% | 🇺🇸 USA |
 Bio-Rad Laboratories BIO | -3.32 | 774.62% | 🇺🇸 USA |
 Trinity Biotech
TRIB | -0.2954 | -22.09% | 🇮🇪 Ireland |
 OraSure Technologies OSUR | -7.79 | 1,953.37% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.